Cognition Therapeutics Inc (CGTX)
0.4612
-0.05
(-9.85%)
USD |
NASDAQ |
Nov 15, 16:00
0.4613
0.00 (0.00%)
After-Hours: 20:00
Cognition Therapeutics Research and Development Expense (TTM): 45.40M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 45.40M |
| March 31, 2024 | 42.32M |
| December 31, 2023 | 37.20M |
| September 30, 2023 | 32.04M |
| June 30, 2023 | 28.64M |
| March 31, 2023 | 29.24M |
| December 31, 2022 | 30.32M |
| September 30, 2022 | 29.46M |
| Date | Value |
|---|---|
| June 30, 2022 | 24.86M |
| March 31, 2022 | 20.66M |
| December 31, 2021 | 18.57M |
| September 30, 2021 | 16.29M |
| June 30, 2021 | 16.01M |
| March 31, 2021 | 13.87M |
| December 31, 2020 | 12.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.89M
Minimum
Dec 2020
45.40M
Maximum
Jun 2024
26.52M
Average
28.64M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| NeuroBo Pharmaceuticals Inc | 21.36M |
| Dermata Therapeutics Inc | 5.648M |
| ZyVersa Therapeutics Inc | 2.153M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |